|3.98 0.06 (1.53%)||12-01 16:00|
|Targets||6-month :||5.18||1-year :||6.05|
|Resists||First :||4.44||Second :||5.18|
|Supports||First :||3.86||Second :||3.5|
|MAs||MA(5) :||3.81||MA(20) :||3.82|
|MA(100) :||4.49||MA(250) :||4.23|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||65.2||D(3) :||47.8|
|52-week||High :||6.69||Low :||3|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ XBIT ] has closed below upper band by 9.0%. Bollinger Bands are 33.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||3.99 - 4.01||4.01 - 4.03|
|Low:||3.71 - 3.73||3.73 - 3.75|
|Close:||3.95 - 3.98||3.98 - 4.01|
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||30 (M)|
|Held by Insiders||1.98e+007 (%)|
|Held by Institutions||35.1 (%)|
|Shares Short||277 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-12 %|
|Return on Assets (ttm)||361.6 %|
|Return on Equity (ttm)||-9.7 %|
|Qtrly Rev. Growth||300000 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||-7.12|
|Qtrly Earnings Growth||-0.8 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-18 (M)|
|Price to Book value||0|
|Price to Sales||-0.56|
|Price to Cash Flow||0.75|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|